Participated · Series C · May 2026

Founded in 2016 by Racem Flazi, Mehdi Ouchallal and Samuel Goldstein, LegalPlace provides services to entrepreneurs for company creation and ongoing administrative and legal management. Through acquisitions, including the recent purchase of competitor Legalstart, the group now claims to cover about 20% of company creations in France and employs roughly 500 people. The company sold its Kanoon document-generation platform to Silae to concentrate on a unified "super app" for very small businesses. LegalPlace is developing new platform features such as an instant company-formation product and an AI agent to manage accounting and formalities. Management is targeting €100 million in revenue in 2026 and is preparing a European expansion that may be accompanied by further fundraising.

Participated · Series B · Jan 2026

Tenpoint Therapeutics, Ltd. is a global commercial biotech company focused on rejuvenating vision in the aging eye. Its lead product, YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution 2.75% / 0.1%), is the first and only dual-agent eye drop approved for presbyopia, a condition that affects about 128 million people in the United States and roughly 2 billion worldwide. The company plans to launch YUVEZZI in early Q2, supported by a leadership team with extensive ophthalmology experience. Tenpoint emphasizes real-world needs by partnering closely with eye-care professionals to bring innovative treatments to market. Financially, the firm recently bolstered its balance sheet with $85 million in Series B equity financing and a $150 million non-dilutive term loan facility, bringing in both new and existing blue-chip investors. This capital positions Tenpoint to execute a large-scale commercial rollout while continuing to build its pipeline of therapies for the aging eye.

Led · Equity · Oct 2025

Payflow has developed a financial-wellbeing application that employers provide to staff as a benefit, enabling workers to access the portion of salary they have already earned free of charge. Companies pay a fixed monthly fee—around €1,500 for a 1,000-person workforce—and typically see staff turnover drop by about 21%, generating an ROI more than 20× the initial cost. Operating in Spain, Portugal, Colombia and Peru, the startup serves over 1,000 corporate clients, including large brands such as Lidl, Mango, Decathlon and Five Guys, and claims leadership in these markets. With just 55 employees, Payflow exceeds €7 million in annual revenue, maintains a gross margin above 80%, and has grown roughly 60% year-over-year while producing a 5% EBITDA margin, pushing its Rule of 40 metric above 65%. The company has secured €26 million in equity capital and over €30 million in debt, including €20 million from BBVA Spark. Founders Benoît Menardo and Avinash Sukhwani aim to keep expanding across Iberia and Latin America while achieving full profitability by 2026. Investors highlight Payflow’s rapid yet efficient customer acquisition, noting payback periods of just four months.

Participated · Equity · Oct 2025

Founded in 2016 by Clément Meslin, Philippe Riveron, Raphaël Droissart and Rémi Lesaint, Edflex offers a digital learning platform that aggregates content from more than 10,000 publishers across 25 formats. Its new product, Edflex Copilot, leverages generative AI to deliver immersive simulations with voice and emotion, granular progress analytics, contextual recommendations and automated skills assessment. The solution integrates natively with tools such as Microsoft Teams, Workday, SAP and 360Learning so that learning occurs inside the flow of work. Edflex serves over 300 corporate customers and 1.5 million users in 140 countries, supported by a workforce of 100+ employees spread across France, Italy, the United States and Canada. The company executed its first acquisition in Italy in 2024 and plans to open a North American office in 2025 while localizing content to meet regional regulations. Its model of continuous, curated learning positions it as a European alternative to large U.S. and Asian digital-learning platforms. Edflex became profitable on its historical markets in 2025 and has now raised a cumulative €32 million since 2021 to accelerate its AI roadmap and international expansion.

Participated · Series B · Feb 2025

Newronika develops an adaptive deep brain stimulation (DBS) platform that integrates real-time patient neural data and machine learning to optimize therapy and reduce side effects. The company holds a CE Mark and has received an Investigational Device Exemption (IDE) from the FDA, and recently received a grant from The Michael J. Fox Foundation. The €13.6 million Series B financing will accelerate clinical validation and commercialization of its proprietary adaptive DBS system. Newronika plans to advance its product pipelines, recruit top-tier talent, and establish strategic collaborations to strengthen its position at the intersection of medical device engineering and neuroscience. Headquartered in Milan, Italy, the company positions its technology as a next-generation personalized neuromodulation solution. The funding supports Newronika's push toward broader clinical and commercial deployment. Newronika develops an adaptive deep brain stimulation (DBS) system, the Alpha-DBS, designed to automatically adjust therapy to patients’ needs. The company has a CE-marked deep brain stimulation system and is developing proprietary adaptive DBS technology with licensed patents and published initial clinical data. The €2.5M EIC Accelerator grant will fund a multi-center European pivotal trial comparing adaptive DBS to conventional DBS in advanced Parkinson’s disease patients and support product development for European market readiness. Newronika was founded in 2009 by a multidisciplinary team led by Dr. Alberto Priori with participation from Fondazione IRCCSS Ca’ Granda Ospedale Maggiore Policlinico and the University of Milan. The company is venture-backed and is completing feasibility trials at several leading DBS centers. Its platform technology is positioned for application to other central nervous system disorders. Newronika is a Milan-based neurotech startup that has developed an implantable medical device for deep brain stimulation using a retroaction “closed loop” system. The company's technology is initially targeted at patients affected by Parkinson’s disease. Newronika is a spin-off of Policlinico di Milano and Università degli Studi di Milano and is led by CEO Lorenzo Rossi and CFO Alain Garcinuño. It raised €8.4m in funding to advance its clinical and regulatory work. Proceeds will be used to complete its first human clinical study and to obtain CE marking and IDE acknowledgement from the FDA. The company says it is ready to start the clinical experiment to make the technology available to patients. Newronika develops a patented closed‑loop Deep Brain Stimulation (DBS) technology that records brain activity and modulates neurostimulation based on Parkinson’s fluctuations and patient conditions. The company’s core product is an implantable device for neuromodulation therapy aimed at treating Parkinson’s disease. Newronika is a spin‑off from Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico di Milano and Università degli Studi di Milano. It has completed a first human feasibility and safety study involving 17 patients, with results to be released soon. The firm intends to use newly raised funds to continue clinical studies, finalize development of its implantable device and complete the regulatory clinical path. The company holds patented technology developed from research by Prof. Alberto Priori and Lorenzo Rossi, PhD.